HSP

CH5164840 is a potent inhibitor of the N-terminal domain of Hsp90a, exhibiting a high binding affinity with a Kd value of 0.52 nM. This compound demonstrates significant anti-proliferative effects against various human cancer cell lines, including HCT116 and NCI-N87, with IC50 values of 0.15 μM and 0.066 μM, respectively. Additionally, CH5164840 has an oral bioavailability profile with a half-life of 2.64 hours, indicating its potential for effective antitumor applications in therapeutic settings.

HSP90-IN-19 is a potent inhibitor of heat shock protein 90 (Hsp90), identified for its effective inhibitory activity with an IC50 value of 0.27 μM. This compound is relevant for studies investigating viral infections, neurodegenerative diseases, and inflammatory processes. Its ability to modulate cellular stress response pathways makes it a valuable tool in biochemical research and drug development efforts targeting Hsp90.

EV206 is a selective binder to the N-terminal domain of Hsp70, functioning as an apoptosis inducer. It promotes the degradation of Hsp70 through the ubiquitin-proteasome pathway, leading to reduced protein stability and inhibition of cellular growth. EV206 effectively induces apoptotic cell death in non-small cell lung cancer cells, suppresses colony formation, and downregulates markers associated with cancer stem cells. Additionally, it demonstrates anti-tumor activity in H460 xenograft models. This compound serves as a valuable tool for research in non-small cell lung cancer.

KNK423 is a specific inhibitor of heat shock protein (HSP) synthesis, targeting HSP70. This compound enhances the efficacy of Amphotericin B against resistant strains of Aspergillus terreus by disrupting HSP expression. KNK423 is valuable for research in cancer therapy and bacterial infection mechanisms.

Hsp90-IN-47 is a potent Hsp90 inhibitor, demonstrating an IC50 of 0.014 μM against Hsp90α. This compound exhibits significant antifungal properties, particularly when used in combination with Fluconazole, enhancing efficacy against fluconazole-resistant strains of Candida albicans. Additionally, Hsp90-IN-47 shows promising antitumor activity, particularly in acute myeloid leukemia and non-small cell lung cancer research applications.